Now I have enough information to write the final review. Let me compile it:

---

## Summary

This paper proposes an end-to-end multi-view diabetic retinopathy (DR) grading framework with two modules: GALP, which generates grade-conditioned evidence maps from stage-wise auxiliary classifiers and selects top-K spatial regions as "lesion proposals"; and LGRF, which fuses cross-view information via gated mixture-of-experts and top-K-weighted cross-view attention. The core thesis is that self-derived CAM-based proposals can substitute for costly external lesion/vessel annotations, and results on MFIDDR (4-view) and DRTiD (2-view) demonstrate competitive or superior performance to externally-informed baselines.

## Strengths

- **End-to-end DRTiD results outperform all externally-informed methods (Table 3).** The method achieves 76.0% accuracy without any external annotations, surpassing CrossFIT (75.6%, using OD and macula coordinates) and CVSA (74.7%, using vessel masks). This is strong empirical evidence that self-derived proposals can effectively substitute for expert annotations.

- **Competitive lesion-free performance on MFIDDR (Table 1).** Without external annotations, the method achieves 83.9% accuracy, surpassing CVSA with vessel masks (82.6%) and LFMVDR with lesion maps (82.2%). On Grade 4, the with-lesion variant achieves 51.6% F1, a substantial improvement over SMVDR-W (40.8%).

- **Clean ablation demonstrating each module's contribution (Table 4).** Removing GALP drops accuracy from 83.9% to 82.7% (−1.2%), removing the expert pool to 82.6% (−1.3%), and removing the full LGRF to 82.3% (−1.6%). Each variant directly corresponds to a specific contribution claim, making the ablation well-designed.

- **Well-structured problem motivation.** The three-stage taxonomy (single-view → multi-view → revisiting end-to-end limitations) and the articulation of annotation cost and workflow burden provide clear, practical motivation grounded in real clinical deployment constraints.

## Weaknesses

### Fatal
None.

### Major

- **"Lesion proposal" claim is unvalidated despite ground-truth lesion masks being available.** The entire narrative — title, abstract, contribution statements (line 43: "recovering small, low-contrast lesions"), and framing — is built on the assumption that GALP's CAM-based evidence maps identify actual pathological lesions. However, line 91 states: "These regions are interpreted as grade-related (i.e., lesion) areas." CAM-based attribution maps are known to highlight non-lesion features (optic disc, major vessels, artifacts) that correlate with disease severity. Critically, MFIDDR provides ground-truth lesion segmentation masks (line 185: "The provider also releases lesion segmentation masks"), yet the paper provides zero validation: no GEM visualizations overlaid on fundus images, no IoU against lesion masks. Without this evidence, the contribution is better characterized as "grade-discriminative region selection for guided fusion" rather than "lesion proposal generation." This gap between the claimed contribution and what is demonstrated is the paper's central weakness.

- **No vanilla backbone-controlled baseline in ablation.** The proposed method uses Swin-B while several baselines use weaker backbones (MVCNN_R: ResNet50, MVCNN_V: VGG19, per lines 240–241). The ablation (Table 4) compares only against Swin-B removal variants that still use GALP/LGRF components. The "w/o LGRF" variant (82.3%) eliminates the fusion module but "simply concatenates lesion proposals with cross-view tokens" (line 286), so it still uses GALP-generated proposals. A vanilla Swin-B multi-view baseline (e.g., simple concatenation of per-view features) is needed to disentangle backbone capacity from module contributions.

### Minor

- **No variance or significance reporting.** All results are single numbers on a single train/test split (MFIDDR: 8,613 eyes, DRTiD: 3,100 eyes). On MFIDDR, the differences between the method and the closest baselines are small: 0.3% below WGLIN (84.2%) and 0.1% below SMVDR-M (84.0%). Without variance estimates, it is impossible to assess whether these margins are meaningful.

- **Conclusion overstates the SOTA claim.** The conclusion states "our method achieves SOTA performance" without qualification. On MFIDDR, the core contribution (w/o lesion, 83.9%) actually trails WGLIN (84.2%) and SMVDR-M (84.0%). Only the with-lesion variant (84.6%) achieves top performance, but this uses external annotations — the very dependency the paper aims to reduce.

- **Adjacent (cyclic) view fusion in LGRF is unjustified.** Line 123 restricts cross-view fusion to adjacent cyclic views (j = i+1 mod N) for 4-view MFIDDR. The views are "captured from distinct angles" (line 185) with no stated natural ordering, making the cyclic adjacency appear arbitrary. No motivation or ablation comparing against all-pairs fusion is provided.

## Nice-to-Haves
- Visualization of GEMs overlaid on fundus images to show whether the proposals highlight actual lesions or other discriminative features.
- DRTiD ablation to verify that the ablation findings generalize across datasets.
- Separating the benefit of intermediate auxiliary supervision from spatial proposal selection (auxiliary loss alone vs. full GALP with top-K selection).
- Unspecified hyperparameter tuning procedure — were α, M, K₂ tuned on a validation set or the test set?

## Removed Points
These points are flagged to be removed, treat them with caution:
- Backbone pretraining strategy differences (ImageNet vs EyePACS): follows prior work conventions, standard in the field.
- "Stage 4 exclusion from auxiliary supervision unexplained": minor design choice; stage 4 hosts the final classifier.
- The critic's "circular reasoning" framing is somewhat unfair — the paper does say "interpreted as" (line 91), though it then builds the entire narrative as if this is established fact.

## Novel Insights
The DRTiD result — 76.0% end-to-end accuracy outperforming all externally-informed methods including CrossFIT (75.6%) and CVSA (74.7%) — provides genuinely compelling evidence that self-derived CAM-based proposals can substitute for expert-annotated cues in multi-view DR grading. This is a practically significant finding for clinical deployment, though the paper would benefit from exploring why this holds on DRTiD but the margin is tighter on MFIDDR (where the w/o lesion variant trails WGLIN and SMVDR-M).

## Suggestions
- Add GEM visualizations overlaid on MFIDDR fundus images and compute IoU against the available ground-truth lesion masks to validate (or honestly reframe) the "lesion proposal" claim.
- Add a vanilla Swin-B multi-view baseline (concatenation of per-view features) to the ablation table to disentangle backbone contribution from module contribution.
- Report mean ± std over 3–5 runs on MFIDDR to support claims of improvement over the closest baselines.
- Qualify the SOTA claim in the conclusion to distinguish between the with-lesion and w/o lesion configurations.

## Calibration Report

### Anchors Retrieved

**Round 1 — Bracketing:**

| Path | Avg Score | Round | Comparison |
|------|-----------|-------|------------|
| nSDOkm0SKo.md | 1.00 | R1 | Fundamentally flawed financial analysis; far weaker than this paper |
| 5lUdTogEL3.md | 1.00 | R1 | Rejected re-identification paper; far weaker |
| SNNdmfqWFu.md | 3.40 | R1 | Incremental multi-view representation learning; weaker than this paper |
| ZBH4fqQwJQ.md | 4.75 | R1 | Multi-view diffusion with limited novelty; weaker than this paper |
| 8g5Ye3c3oR.md | 4.50 | R1 | Weakly supervised medical lesion segmentation; interesting ideas but poorly written, similar domain |
| 6NO5UVWvo6.md | 4.50 | R1 | Point-supervised medical segmentation; incremental, similar domain |
| FUgrjq2pbB.md | 6.50 | R1 | MVDream multi-view diffusion; stronger contribution, accepted |
| M3kBtqpys5.md | 6.25 | R1 | Trusted multi-view classification; competitive contribution |
| QQBPWtvtcn.md | 7.67 | R1 | LVSM view synthesis; strong contribution, accepted |
| P4o9akekdf.md | 8.00 | R1 | NoPoSplat; strong contribution, accepted |
| UKZqSYB2ya.md | 2.50 | R1 | CT anomaly detection; incomplete methodology |
| TUUjIWntkU.md | 2.50 | R1 | Explainable medical clustering; limited contribution |
| MrOefpTvev.md | 2.33 | R1 | Texture transformer for medical images; limited contribution |
| 8g5Ye3c3oR.md | 4.50 | R1 | CoinGAN weakly supervised lesion segmentation; similar domain, rejected |
| qtqvuBmhxU.md | 5.75 | R1 | MONICA medical benchmark; practical but lacks novelty, rejected |
| QG31By6S6w.md | 6.25 | R1 | Malenia 3D zero-shot lesion segmentation; accepted medical imaging |
| l0t2rumAvR.md | 6.25 | R1 | StructuralGLIP medical detection; accepted |
| IwgmgidYPS.md | 6.00 | R1 | MedTrinity-25M dataset; accepted |
| HNOo4UNPBF.md | 6.50 | R1 | Scale-aware anomaly detection; accepted |
| 3b9SKkRAKw.md | 8.00 | R1 | LeFusion lesion-focused diffusion; strong medical contribution |

### Bracketing Analysis

**Initial bracket: between 5.0 and 6.5**

The paper is clearly above the reject range (2–4.5): the method is technically sound, well-presented, and has compelling empirical results (DRTiD end-to-end beating all externally-informed methods). The closest domain-relevant anchor is CoinGAN (4.50, reject) which had unclear presentation and limited insights — this paper is substantially better.

The paper sits below strong accept papers like Malenia (6.25) which had more comprehensive evaluation across datasets and modalities, and LeFusion (8.00) which had a fundamentally stronger contribution. However, it is comparable to MedTrinity-25M (6.00, accept) in contribution scope and practical value.

The unvalidated "lesion proposal" claim — given that ground-truth lesion masks are available but unused — is the primary factor holding the score back from the 6.25+ range. The missing backbone-controlled ablation is secondary. However, the genuinely strong DRTiD end-to-end results and the clean ablation prevent a score below 5.5.

**Final score: 6.0** — The paper presents a well-executed method with strong empirical evidence on DRTiD and competitive MFIDDR results. The central weakness (unvalidated "lesion proposal" claim despite available ground-truth) prevents a higher score, but the genuine practical contribution and technical soundness keep it above reject territory. This is a solid applied paper with a clear reframing opportunity.

MY FINAL SCORE: <score>6.0</score>
MY FINAL DECISION: <decision>Accept</decision>